Javier Ruiz-Guiñazú

Dr. Javier Ruiz-Guiñazú


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Vaccine
Verified
Journal Article
Open access
FSFrank Struyf
Frank Struyf
KHKarin Hardt
Karin Hardt
RRRian Van Rampelbergh
Rian Van Rampelbergh
Georgi ShukarevGeorgi Shukarev
Georgi Shukarev
AIAjinkya Inamdar
Ajinkya Inamdar
MDMacaya Douoguih
Macaya Douoguih
Thrombosis with thrombocytopenia syndrome (TTS) is a very rare disorder described after vaccination with adenoviral vector-based COVID-19 vaccines. Co-occurring thrombosis with thrombocytopenia reported after vaccination can be a proxy for identification of TTS. Descriptive database review of all cases of co-occurring (within 42 days) thrombosis with thrombocytopenia in participants in Ad26.COV2.S clinical trials or recipients of Ad26.COV2.S in real-world clinical practice. Cases were retrieved from Janssens' clinical trial and Global Medical Safety databases. There were 34 cases of co-occurring thrombosis with thrombocytopenia in Ad26.COV2.S recipients (46 per 100,000 person-years) and 15 after placebo (75 per 100,000 person-years) in clinical trials. Among Ad26.COV2.S recipients, mean age at the time of the event was 63 years (range 25-85), 82 % were male, mean time-to-onset 112 days (range 8-339) post-last Ad26.COV2.S dose, 26 events occurred post-dose-1, and 7 within a 28-day risk window post-vaccination. Diagnostic certainty was evaluated using Brighton Collaboration, US Centers for Disease Control and Prevention, and European Medicines Agency Pharmacovigilance Risk Assessment Committee case definitions. One case met the highest level of diagnostic certainty for all 3 definitions. There were 355 spontaneous reports of co-occurring thrombosis with thrombocytopenia in the Global Medical Safety database, 47 % males, 85 % within 28-days after vaccination. Twenty-seven cases met the highest level of diagnostic certainty for all definitions, 21 female, 19 with cerebral venous sinus thrombosis, age-range 18-68 years. Time-to-onset was 7-14 days post-vaccination in 20 cases. There were 8 fatalities. TTS induced by Ad26.COV2.S is very rare. Most co-occurring thrombosis with thrombocytopenia does not constitute TTS.

9 December 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ADAnna Dari
Anna Dari
MBMuriel Boulton
Muriel Boulton
MNMartine Neyens
Martine Neyens
MGMathieu Le Gars
Mathieu Le Gars
BVBelén Valenzuela
Belén Valenzuela
JRJuan José Pérez Ruixo
Juan José Pérez Ruixo
Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID‐19) is critical for informing the duration of protection and appropriate booster timing. We developed a mechanistic model to characterize the time course of humoral immune responses in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)–seronegative adults after primary vaccination with the Janssen COVID‐19 vaccine, Ad26.COV2.S. The persistence of antibody responses was quantified through mechanistic modeling‐based simulations. Two biomarkers of humoral immune responses were examined: SARS‐CoV‐2 neutralizing antibodies determined by wild‐type virus neutralization assay (wtVNA) and spike protein‐binding antibodies determined by indirect spike protein enzyme‐linked immunosorbent assay (S‐ELISA). The persistence of antibody responses was defined as the period of time during which wtVNA and S‐ELISA titers remained above the lower limit of quantification. A total of 442 wtVNA and 1,185 S‐ELISA titers from 82 and 220 participants, respectively, were analyzed following administration of a single dose of Ad26.COV2.S (5 × 1010 viral particles). The mechanistic model adequately described the time course of observed wtVNA and S‐ELISA serum titers and its associated variability up to 8 months following vaccination. Mechanistic model‐based simulations show that single‐dose Ad26.COV2.S elicits durable but waning antibody responses up to 24 months following immunization. Of the estimated model parameters, the production rate of memory B cells was decreased in older adults relative to younger adults, and the antibody production rate mediated by long‐lived plasma cells was increased in women relative to men. A steeper waning of antibody responses was predicted in men and in older adults.

1 December 2020 in Expert Review of Vaccines
Verified
Journal Article
Open access
MNMarta Nunes
Marta Nunes
MMMarta Moreira
Marta Moreira
AKAnthonet Koen
Anthonet Koen
NNNadia van Niekerk
Nadia van Niekerk
LJLisa Jose
Lisa Jose
SMShabir Ahmed Madhi
Shabir Ahmed Madhi
Background: We evaluated bacterial nasopharyngeal carriage (NPC) prevalence and cumulative acquisition following 7-valent pneumococcal conjugate vaccine (PCV7) or pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administration. Methods: Participants were children from two clinical trials in a South African center who received PCV7 (n=250) or PHiD-CV (n=100) at ~6 weeks, ~14 weeks, and ~9-10 months of age, and were enrolled between Dec2009-Apr2010 and Mar2009-May2010 in the PCV7 and PHiD-CV studies, respectively. Sample collection, most microbiological assessments, and data re-analysis methods were identical. Results: NPC prevalence of any pneumococcal serotype was 18.5% and 17.0% at pre-vaccination, and 63.1% and 67.3% in 24-27 month-old children among PCV7 and PHiD-CV recipients, respectively. In 24-27 month-old children, 96.1% and 99.0% of PCV7 and PHiD-CV recipients had acquired ≥1 pneumococcal serotype, 53.7% and 62.9% ≥1 PCV7 serotype, 1.5% and 3.1% ≥1 of serotypes 1, 5 or 7F, 23.2% and 19.6% serotype 6A, 23.2% and 21.7% serotype 19A, 88.7% and 91.0% H. influenzae, and 50.3% and 62.9% Staphylococcus aureus, respectively. Conclusions: This analysis of two concurrent clinical trials did not reveal differences in bacterial NPC prevalence or acquisition in PCV7- and PHiD-CV-vaccinated children. Trial Registration: South African National Clinical Trial Register (NHREC DOH-27-0511-299); ClinicalTrials.gov (NCT00829010).

15 September 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
ADAnna Dari
Anna Dari
PJPhilippe Jacqmin
Philippe Jacqmin
YIYuki Iwaki
Yuki Iwaki
MNMartine Neyens
Martine Neyens
MGMathieu Le Gars
Mathieu Le Gars
JPJuan José Pérez‐Ruixo
Juan José Pérez‐Ruixo
Mechanistic model‐based simulations can be deployed to project the persistence of humoral immune response following vaccination. We used this approach to project the antibody persistence through 24 months from the data pooled across five clinical trials in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)‐seronegative participants following vaccination with Ad26.COV2.S (5 × 1010 viral particles), given either as a single‐dose or a homologous booster regimen at an interval of 2, 3, or 6 months. Antibody persistence was quantified as the percentage of participants with detectable anti‐spike binding and wild‐type virus neutralizing antibodies. The projected overall 24‐month persistence after single‐dose Ad26.COV2.S was 70.5% for binding antibodies and 55.2% for neutralizing antibodies, and increased after any homologous booster regimen to greater than or equal to 89.9% for binding and greater than or equal to 80.0% for neutralizing antibodies. The estimated model parameters quantifying the rates of antibody production attributed to short‐lived and long‐lived plasma cells decreased with increasing age, whereas the rate of antibody production mediated by long‐lived plasma cells was higher in women relative to men. Accordingly, a more pronounced waning of antibody responses was predicted in men aged greater than or equal to 60 years and was markedly attenuated following any homologous boosting regimen. The findings suggest that homologous boosting might be a viable strategy for maintaining protective effects of Ad26.COV2.S for up to 24 months following prime vaccination. The estimation of mechanistic modeling parameters identified the long‐lived plasma cell pathway as a key contributor mediating antibody persistence following single‐dose and homologous booster vaccination with Ad26.COV2.S in different subgroups of recipients stratified by age and sex.

4 May 2024 in Vaccine
Verified
Journal Article
Open access
VCVicky Cárdenas
Vicky Cárdenas
MGMathieu Le Gars
Mathieu Le Gars
CTCarla Truyers
Carla Truyers
JRJavier Ruiz-Guiñazú
Javier Ruiz-Guiñazú
FSFrank Struyf
Frank Struyf
JSJerald Sadoff
Jerald Sadoff
Background: A single dose of Ad26.COV2.S is well-tolerated and effective in preventing moderate-to-severe disease outcomes due to COVID-19. We evaluated the impact of dose level, number of doses, and dose interval on immunogenicity, reactogenicity, and safety of Ad26.COV2.S in adults. Anamnestic responses were also explored. Methods: This randomised, double-blind, placebo-controlled, Phase 2a study was conducted in adults aged 18–55 years and ≥ 65 years (NCT04535453). Four dose levels (1.25 × 1010, 2.5 × 1010, 5 × 1010, and 1 × 1011 viral particles [vp], single and 2-dose schedules, and dose intervals of 56 and 84 days, were assessed. Four or 6 months post-primary vaccination, Ad26.COV2.S 1.25 × 1010 vp was given to evaluate anamnestic responses. Humoral and cell-mediated immune responses were measured. Reactogenicity and safety were assessed in all participants. Results: All Ad26.COV2.S schedules induced humoral responses with evidence of a dose response relationship. A single dose of Ad26.COV2.S (5 × 1010 vp) induced antibody and cellular immune responses that persisted for up to at least 6 months. In the 2-dose regimens, antibody responses were higher than 1-dose regimens at comparable dose levels, and the magnitude of the immune response increased when the interval between doses was increased (84 days vs 56 days). Rapid, marked immune responses were observed in all groups after vaccine antigen exposure indicating immune memory. Durable immune responses were observed in all groups for up to at least 6 months post-antigen exposure. Strong and consistent correlations between neutralising and binding antibodies were observed CD4 + and CD8 + T cell responses were similar after all regimens. Reactogenicity within 7 days post-vaccination tended to be dose-related. Conclusion: The study supports the primary, single dose schedule with Ad26.COV2.S at 5 × 1010 vp and homologous booster vaccination after a 6 month interval. Rapid and marked responses to vaccine antigen exposure indicate induction of immune memory by 1- and 2-dose primary vaccination.

1 November 2020 in Expert Review of Vaccines
Verified
Journal Article
Open access
ASAbiel Mascareñas de Los Santos
Abiel Mascareñas de Los Santos
MRMiguel Angel Rodríguez-Weber
Miguel Angel Rodríguez-Weber
PSPedro Sánchez-Márquez
Pedro Sánchez-Márquez
MTMagali Traskine
Magali Traskine
RCRoberto Carreño-Manjarrez
Roberto Carreño-Manjarrez
DBDorota Borys
Dorota Borys
We assessed the safety and immunogenicity of 2+1 infant regimens initiated with the 13-valent pneumococcal conjugate vaccine (PCV13) and completed with the pneumococcal non-typeable Haemophilus inf...